A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry.

Autor:	Teo J; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore.; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore., Mirenska A; Clinical Biomarkers, Zellkraftwerk, Bosestrasse 4, D-04109 Leipzig, Germany.; Clinical Biomarkers, Zellkraftwerk, Bosestrasse 4, D-04109 Leipzig, Germany., Tan M; Clearbridge BioMedics Pte Ltd, 81 Science Park Drive, The Chadwick, #02-03, Singapore Science Park 1, 118257, Singapore.; Clearbridge BioMedics Pte Ltd, 81 Science Park Drive, The Chadwick, #02-03, Singapore Science Park 1, 118257, Singapore., Lee Y; Clearbridge BioMedics Pte Ltd, 81 Science Park Drive, The Chadwick, #02-03, Singapore Science Park 1, 118257, Singapore.; Clearbridge BioMedics Pte Ltd, 81 Science Park Drive, The Chadwick, #02-03, Singapore Science Park 1, 118257, Singapore., Oh J; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore.; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore., Hong LZ; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore.; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore., Wnek R; Translational Molecular Biomarkers, Merck Research Laboratories, Merck & Co. Inc., Rahway, NJ 07065, USA.; Translational Molecular Biomarkers, Merck Research Laboratories, Merck & Co. Inc., Rahway, NJ 07065, USA., Yap YS; Department of Medical Oncology, National Cancer Centre Singapore, Singapore.; Department of Medical Oncology, National Cancer Centre Singapore, Singapore., Shih SJ; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore.; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore., S Bhagat AA; Clearbridge BioMedics Pte Ltd, 81 Science Park Drive, The Chadwick, #02-03, Singapore Science Park 1, 118257, Singapore.; Clearbridge BioMedics Pte Ltd, 81 Science Park Drive, The Chadwick, #02-03, Singapore Science Park 1, 118257, Singapore., Chin CL; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore.; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore., Skibinski DA; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore.; Translational Biomarkers, Translational Medicine Research Centre, Merck Research Laboratories, MSD, Singapore.
Jazyk:	angličtina
Zdroj:	Future science OA [Future Sci OA] 2017 Sep 04; Vol. 3 (4), pp. FSO244. Date of Electronic Publication: 2017 Sep 04 (Print Publication: 2017).
DOI:	10.4155/fsoa-2017-0079
Abstrakt:	Aim: Expression of PD-L1 in the tumor is associated with more favorable responses to anti-PD-1 therapy in multiple cancers. However, obtaining tumor biopsies for PD-L1 interrogation is an invasive procedure and challenging to assess repeatedly as the disease progresses. Materials & Methods: Here we assess an alternative, minimally invasive approach to analyze blood samples for circulating tumor cells (CTCs) that have broken away from the tumor and entered the periphery. Our approach uses sized-based microfluidic CTC enrichment and subsequent characterization with microfluidic-based cytometry (chipcytometry). Conclusion: We demonstrate tumor-cell detection and characterization for PD-L1, and other markers, in both spiked and patient samples. This preliminary communication is the first report using chipcytometry for the characterization of CTCs. Competing Interests: Financial & competing interests disclosure J Teo, J Oh, LZ Hong, R Wnek, C-L Chin and DAG Skibinski are all currently employed by MSD. A Mirenska is currently employed by Zellkraftwerk. M Tan, Y Lee and AAS Bhagat are all currently employed by Clearbridge Biomedics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu